Axon Enterprise, Inc.'s 10-K, read.

Axon's revenue is growing fast, with 9-month 2026 net sales up about 32% and a large $10.2 billion backlog of remaining performance obligations, and it swung to positive operating income. However, reported profits lean heavily on investment gains, operating cash flow has nearly stalled, and the company is funding growth and acquisitions with more debt, equity-linked securities, and stock compensation.

• Operating cash flow nearly stalled: net cash from operations was $8.2 million for the nine months ended September 30, 2026, versus a net outflow of $5.9 million for the nine months ended September 30, 2025, as receivables, contract assets, and inventory absorbed cash.
• Net income depends on non-operating gains: nine-month 2026 other income was $255.7 million, mostly strategic investment gains, while operating income was $118.1 million.
• Rising debt and convertible exposure: notes payable principal reached $2.9 billion after a $1.15 billion 0% convertible issuance in September 2026, and the company used a capped call on the new notes.
• Inventory and working capital build: inventory rose to $579 million from $342 million at year-end 2025, and contract assets rose to $867 million, raising execution and collection risk.
• Acquisition-driven goodwill and integration risk: goodwill increased to $1.89 billion from $1.37 billion. Business combinations used $552.0 million of cash, net of cash acquired, in the nine months; the 10-K describes the Carbyne acquisition ($625.0 million base price, funded from cash on hand) as subsequent to year-end.

Not investment advice — general research, the same for every reader. You make your own calls.